Werewolf Therapeutics Inc. (NASDAQ:HOWL) shares are trending on Friday.
Shares of the Massachusetts-based clinical-stage biopharmaceutical company surged 89.94% to $0.82 in after-hours trading on Thursday, following disclosure that it sold its pre-clinical INDUCER and INDUKINE technology platforms to EMD Serono Research & Development Institute Inc.
INDUCER and INDUKINE are Werewolf’s pre-clinical drug-development platforms, designed to engineer conditionally-activated immune-stimulating molecules that target tumors while limiting effects on healthy tissue.
EMD Serono Research & Development Institute Inc. is a specialized biopharmaceutical company that operates as a subsidiary of Merck KGaA.
Deal Brings Fresh Non-Dilutive Cash
